Effect of Ca2+ blocking agents on the metabolism of low density lipoproteins in human skin fibroblasts.
D001552:Benzazepines / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003992:Dibucaine / Q000494:pharmacology; D004110:Diltiazem / Q000494:pharmacology*; D005275:Fendiline / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D005711:Gallopamil / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008077:Lipoproteins, LDL / Q000378:metabolism*; D009543:Nifedipine / Q000494:pharmacology*; D010627:Phenethylamines / Q000494:pharmacology*; D011299:Prenylamine / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D014268:Trifluoperazine / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology*
D001552:Benzazepines; D002121:Calcium Channel Blockers; D008077:Lipoproteins, LDL; D010627:Phenethylamines; D011725:Pyridines; D014268:Trifluoperazine; D005711:Gallopamil; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D011299:Prenylamine; D003992:Dibucaine; D005275:Fendiline